BR112019012253A2 - inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação - Google Patents

inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação Download PDF

Info

Publication number
BR112019012253A2
BR112019012253A2 BR112019012253A BR112019012253A BR112019012253A2 BR 112019012253 A2 BR112019012253 A2 BR 112019012253A2 BR 112019012253 A BR112019012253 A BR 112019012253A BR 112019012253 A BR112019012253 A BR 112019012253A BR 112019012253 A2 BR112019012253 A2 BR 112019012253A2
Authority
BR
Brazil
Prior art keywords
mmp9
inhibitor
depigmentation
expression
individual
Prior art date
Application number
BR112019012253A
Other languages
English (en)
Portuguese (pt)
Inventor
Jacquemin Clément
Bernard François-Xavier
Seneschal Julien
Boniface Katia
Boukhedouni Nesrine
Original Assignee
Centre Hospitalier Univ Bordeaux
Inst Nat Sante Rech Med
Univ Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Univ Bordeaux, Inst Nat Sante Rech Med, Univ Bordeaux filed Critical Centre Hospitalier Univ Bordeaux
Publication of BR112019012253A2 publication Critical patent/BR112019012253A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112019012253A 2016-12-16 2017-12-15 inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação BR112019012253A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306719 2016-12-16
PCT/EP2017/083182 WO2018109222A1 (en) 2016-12-16 2017-12-15 Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder

Publications (1)

Publication Number Publication Date
BR112019012253A2 true BR112019012253A2 (pt) 2020-01-28

Family

ID=57680192

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019012253A BR112019012253A2 (pt) 2016-12-16 2017-12-15 inibidores de mmp9 e usos dos mesmos na prevenção ou tratamento de um transtorno de despigmentação

Country Status (6)

Country Link
US (1) US10894837B2 (https=)
EP (1) EP3555138A1 (https=)
JP (1) JP7141397B2 (https=)
CN (1) CN110312737A (https=)
BR (1) BR112019012253A2 (https=)
WO (1) WO2018109222A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061351A1 (en) * 2020-09-16 2022-03-24 Incyte Corporation Topical treatment of vitiligo
US20240285497A1 (en) 2021-02-26 2024-08-29 National University Corporation Kobe University Method for evaluating an ability of a test sample to trigger a foreign body reaction in the skin, a method for screening a substance having an ability to inhibit a foreign body reaction in the skin, and an agent for inhibiting a foreign body reaction in the skin
WO2024028417A1 (en) * 2022-08-03 2024-02-08 Institut National de la Santé et de la Recherche Médicale New composition for the treatment and/or prevention of vitiligo
CN119236080A (zh) * 2024-09-29 2025-01-03 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种医药组合物在制备用于治疗多发性硬化药物中的应用
CN120945015B (zh) * 2025-10-17 2025-12-23 潍坊市人民医院(潍坊市公共卫生临床中心、潍坊市职业病医院) 一种适用于黑色素瘤基因检测的脱色素方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59708838D1 (de) 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20040053876A1 (en) 2002-03-26 2004-03-18 The Regents Of The University Of Michigan siRNAs and uses therof
US8101348B2 (en) 2002-07-10 2012-01-24 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. RNA-interference by single-stranded RNA molecules
WO2006037513A1 (en) * 2004-10-09 2006-04-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with matrix metalloproteinase 9 (mmp9)
EP2395996A1 (en) * 2009-02-13 2011-12-21 Indiana University Research and Technology Corporation Compounds and methods for inhibiting mmp2 and mmp9
EP2608809B1 (en) 2010-08-27 2019-05-22 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
WO2013130078A1 (en) 2012-02-29 2013-09-06 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
FR3015986A1 (fr) 2013-12-30 2015-07-03 Lvmh Rech Aptameres inhibiteurs de l'activite enzymatique de la proteine mmp-9
EP2985295A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9

Also Published As

Publication number Publication date
JP2020504719A (ja) 2020-02-13
CN110312737A (zh) 2019-10-08
US20190359730A1 (en) 2019-11-28
EP3555138A1 (en) 2019-10-23
JP7141397B2 (ja) 2022-09-22
US10894837B2 (en) 2021-01-19
WO2018109222A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
Liu et al. MMP-2 and MMP-9 contribute to the angiogenic effect produced by hypoxia/15-HETE in pulmonary endothelial cells
Xu et al. IFN-γ induces gastric cancer cell proliferation and metastasis through upregulation of integrin β3-mediated NF-κB signaling
Veillat et al. Macrophage migration inhibitory factor elicits an angiogenic phenotype in human ectopic endometrial cells and triggers the production of major angiogenic factors via CD44, CD74, and MAPK signaling pathways
US10894837B2 (en) MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
Krautbauer et al. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver
EP2711023B1 (en) Osteogenesis promoter
WO2020018461A1 (en) Compositions and methods of diagnosis and treatment for neurological diseases
Baruch et al. CD38 in cancer-associated fibroblasts promotes pro-tumoral activity
Schneider et al. Targeting of syndecan-1 by micro-ribonucleic acid miR-10b modulates invasiveness of endometriotic cells via dysregulation of the proteolytic milieu and interleukin-6 secretion
Li et al. The NALP1 inflammasome controls cytokine production and nociception in a rat fracture model of complex regional pain syndrome
Kishore et al. Prostaglandin dehydrogenase is a target for successful induction of cervical ripening
Palumbo et al. The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis
KR20150010793A (ko) 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들
US20160130365A1 (en) Methods and compositions for prognosis, diagnosis, and treatment of ADAM8-expressing cancer
Ma et al. Role of relaxin-2 in human primary osteosarcoma
Li et al. IL-6 signaling mediates the germinal center response, IgM production and nociceptive sensitization in male mice after tibia fracture
Huang et al. Cartilage decellularized matrix hydrogel loaded with protocatechualdehyde for targeted epiphycan treatment of osteoarthritis
ES2665849T3 (es) Biomarcador para el diagnóstico de envejecimiento o amiotrofia
EP3336175B1 (en) Three-dimensional model of depigmenting disorder
Sah et al. Novel isonahocol E3 exhibits anti-inflammatory and anti-angiogenic effects in endothelin-1-stimulated human keratinocytes
Sun et al. Elevated plasma levels of tissue inhibitors of metalloproteinase-1 and their overexpression in muscle in human and mouse muscular dystrophy
JP6341859B2 (ja) がんマーカーおよびその用途
WO2015028662A1 (en) Compositions and methods for characterization and amelioration of rheumatoid arthritis
Zhao et al. Borrelia burgdorferi-induced monocyte chemoattractant protein-1 production in vivo and in vitro
US20180364233A1 (en) Methods and pharmaceutical compositions for the treatment of systemic sclerosis

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]